China Pharma Holdings, Inc.CPHI

China Pharma Ltd. priced a registered direct offering of 2.5 million shares of common stock on 22 July 2026, aiming to raise gross proceeds of $5 million at $2.00 per share. The announcement, filed as a 424B prospectus supplement with the SEC, arrives at a moment when the company's latest quarterly filing, for the period ending 31 March 2026, reports cash and cash equivalents of $168,474 and an operating loss of $1.1 million. The offering therefore represents a significant injection relative to the cash on hand, and it is being executed at a per-share price that sits well above the diluted earnings per share of negative $0.04 reported in the same 10-Q.

China Pharma Holdings, Inc. operates through its subsidiaries in the People's Republic of China, developing, manufacturing and marketing pharmaceutical products that are sold on prescription. The company's filings confirm that all of its products have been approved by the National Medical Products Administration for at least one therapeutic indication. The business model relies on a pipeline of technology transfer agreements, where product rights are acquired in exchange for shares issued by the parent company, with future cash royalties payable only if the product is approved and generates net profit. This structure conserves cash but ties commercial returns to regulatory milestones and market uptake.

The 10-Q for the period ending 31 March 2026 shows revenues of $983,536, a net loss attributable to the parent of $1.1 million, and operating loss of $1.1 million. Total assets stood at $45.1 million against liabilities of $8.1 million, producing stockholders' equity of $37.0 million. Net cash used in operating activities was $55,292, and research and development expense was $83,762. Inventory net was $1.5 million, with a decrease in inventories of $247,492. The diluted weighted average number of shares outstanding was 25.6 million.

The technology transfer contracts on file reveal a pattern of share-based consideration. The agreement with Chengdu Bonier Medical Technology Development Co. involved shares worth RMB15 million at US$0.1349 per share, with a 15% net profit royalty. The agreements with Tao Liu and Lihua Li similarly involve share issuance, with 15% and 10% royalties respectively, each contingent on product listing and profitability. These contracts are the company's primary route to expanding its product portfolio without upfront cash payments, but they also create a future dilution path and royalty obligations that only crystallise upon commercial success.

The 424B prospectus supplement frames the offering as general working capital for the platform. The risk for holders is that the new shares increase the diluted count beyond the 25.6 million already reported, while the business is still burning cash from operations and generating quarterly revenue well below the offering size. The evidence does not supply a guidance update, a product launch date, or a profit forecast, so the file remains anchored to the filed numbers and the capital raise mechanics. A subsequent quarterly filing that shows revenue growth, a narrowing operating loss, or a material improvement in cash from operations would materially shift the picture.